Evaluation of EGFR-TK Expression with a 99mTc-Labeled Complex Bearing Quinazoline Pharmacophore
Author(s) -
Zhan Si,
Pengcheng Hu,
Jun Zhou,
Qingyu Lin,
Yan Xiu,
Dengfeng Cheng
Publication year - 2019
Publication title -
cancer biotherapy and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.716
H-Index - 59
eISSN - 1557-8852
pISSN - 1084-9785
DOI - 10.1089/cbr.2019.2846
Subject(s) - quinazoline , biodistribution , cancer research , pharmacophore , epidermal growth factor receptor , tyrosine kinase , medicine , cancer , pharmacology , chemistry , in vitro , receptor , biochemistry , stereochemistry
Objectives: The epidermal growth factor receptor (EGFR) signaling pathway is widely recognized to play an important role in development and progression of many malignant tumors, including lung cancer. The aim of this study was to produce a useful technetium-99m ( 99m Tc) complex for early detection and staging of EGFR-positive tumors. Methods: The authors labeled quinazoline derivative (3-iodinephenyl) quinazoline-4, 6-diamine with 99m Tc using S-acetylmercaptoacetyltriglyglycinate (MAG 3 ) conjugated to quinazoline derivative through 4-[(2-aminoethyl)amino]-4-oxobut-2-enoic acid because it is a bifunctional chelator with an average yield of 93.9% ± 2.5% and radiochemical purity of >98%. Results: In vitro studies indicate that the [ 99m Tc]-complex 13 has high stability in physiological conditions and binds the HCC 827 cells and shows HCC 827 internalization. The biodistribution of the [ 99m Tc]-complex 13 in healthy Institute of Cancer Research mice indicates the rather fast blood clearance through the hepatobiliary system. Conclusion: These preliminary results pave the road for estimating the status of EGFR and monitoring the response to EGFR tyrosine kinase inhibitors as a personalized cancer therapy regimen.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom